FDA accepts NDA for seborrheic keratosis candidate A-101

FDA accepted for review an NDA from Aclaris Therapeutics Inc. (NASDAQ:ACRS) for A-101 to treat seborrheic keratosis (SK). The PDUFA date is Dec. 24...